HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 01, January 2019 – Taiwan medical tourism - Combining medical travel and tourist destination       » New breast cancer drug now available in China       » Chinese scientists make important cancer finding       » Japan's plan to revolutionise healthcare sector with tech       » GSK to buy oncology drugmaker Tesaro for US$5.1 billion       » There is hope for anticancer vaccines      
INSIDE INDUSTRY
SGD34 million initiative to boost pharma manufacturing industry
A*STAR leads initiative with pharma giants and universities to boost manufacturing innovations and speedier production

To drive the transformation of Singapore’s pharmaceutical manufacturing industry and pre-position it for the future economy, the Agency for Science, Technology and Research (A*STAR) has initiated the Pharma Innovation Programme Singapore (PIPS) in partnership with the National University of Singapore (NUS); the Nanyang Technological University (NTU Singapore); the Singapore Institute of Technology (SIT); and leading pharma companies GlaxoSmithKline (GSK), MSD International GmbH (Singapore Branch), and Pfizer Asia Pacific Pte Ltd.

The members of PIPS inked a consortium agreement valued at SGD34 million on 16 October 2018 at the Industrial Transformation Asia-Pacific trade show.

The pharmaceutical manufacturing industry currently contributes over 3 percent to Singapore’s GDP. Eight of the top 10 pharmaceutical companies in the world have facilities in Singapore, and four of the top 10 drugs by global revenue are manufactured here. Since 2000, the sector’s manufacturing output today has grown by more than 3 times.

However, globally the sector is facing sustained pressures on drug pricing, changing expectations of payors, and mounting competition in emerging markets. It is critical for pharmaceutical manufacturing to look at increasing productivity and operational efficiency through leveraging advances in manufacturing technologies and data analytics.

The PIPS consortium will therefore focus on areas such as continuous manufacturing, bio-catalysis, advanced process control and process analytical technology, digitalisation, and enhanced pharmaceutical operations.

The aim is to raise the bar of pharma manufacturing, including more sustainable manufacturing processes and the speedier production of active pharmaceutical ingredients, which will allow drugs to reach patients’ bedsides quicker.

Click here for the complete issue.

NEWS CRUNCH  
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy